The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -61,515 | - |
| Depreciation and amortization | 1,614 | - |
| Stock-based compensation | 9,719 | - |
| Non-cash lease expense | 605 | - |
| Accretion of discount on marketable debt securities | 2,585 | - |
| Prepaid expenses and other current assets | 1,308 | - |
| Accounts payable | 4,897 | - |
| Accrued expenses and other current liabilities | -3,375 | - |
| Operating lease liabilities | -1,070 | - |
| Other | 57 | - |
| Net cash (used in) operating activities | -53,075 | - |
| Redemption of marketable debt securities | 149,610 | - |
| Purchase of marketable debt securities | 107,005 | - |
| Purchase of property and equipment | 9 | - |
| Net cash provided by (used in) investing activities | 42,596 | - |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs | 2 | - |
| Tax withholding payments related to net settlement of restricted common stock | 77 | - |
| Net cash (used in) provided by financing activities | -75 | - |
| Restricted cash | - | 1,472 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -10,554 | - |
| Cash and cash equivalents | - | 10,733 |
| Cash and cash equivalents at beginning of period | 20,945 | - |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | - | 12,205 |
| Cash and cash equivalents at end of period | 10,391 | - |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)